Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 5/20 | 0.56 |
| ▸ | ACHE | P22303 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466400 | 0.92 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5451057 | 0.88 | MEN1 (0.55) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5456545 | 0.88 | CYP3A4 (0.48) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5451064 | 0.87 | MAPT (0.52) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5461510 | 0.86 | MEN1 (0.64) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5280780 | 0.82 | BCHE (0.52) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5242793 | 0.82 | BCHE (0.54) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5453782 | 0.80 | MEN1 (0.56) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5458572 | 0.79 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL5467983 | 0.77 | CYP3A4 (0.48) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | MEN1 2444/4885KMT2A 2911/4885ALDH1A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.